Hisataka Kobayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7669293/publications.pdf

Version: 2024-02-01

291 papers	23,637 citations	8755 75 h-index	9345 143 g-index
296 all docs	296 docs citations	296 times ranked	22160 citing authors

#	Article	IF	Citations
1	CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model. OncoImmunology, 2022, 11, 2019922.	4.6	13
2	Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy. Cancer Immunology, Immunotherapy, 2022, 71, 1877-1887.	4.2	9
3	PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers, 2022, 14, 619.	3.7	4
4	Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts. Biomedicines, 2022, 10, 846.	3.2	3
5	Tumorâ€targeted fluorescence labeling systems for cancer diagnosis and treatment. Cancer Science, 2022, 113, 1919-1929.	3.9	3
6	Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers. Cancer Immunology, Immunotherapy, 2022, 71, 2869-2879.	4.2	6
7	Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration. Cancer Immunology, Immunotherapy, 2022, 71, 3099-3106.	4.2	6
8	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. Cancers, 2022, 14, 2996.	3.7	9
9	Cyanine Phototruncation Enables Spatiotemporal Cell Labeling. Journal of the American Chemical Society, 2022, 144, 11075-11080.	13.7	19
10	Intercellular adhesion moleculeâ€1â€targeted nearâ€infrared photoimmunotherapy of tripleâ€negative breast cancer. Cancer Science, 2022, 113, 3180-3192.	3.9	9
11	Comparison of the Effectiveness of IgG Antibody versus F(abâ€²)₂ Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy. Molecular Pharmaceutics, 2022, 19, 3600-3611.	4.6	1
12	Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens. Communications Biology, 2022, 5, .	4.4	23
13	Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. International Immunology, 2021, 33, 7-15.	4.0	79
14	Near-Infrared Photoimmunotherapy for Cancers of the Gastrointestinal Tract. Digestion, 2021, 102, 65-72.	2.3	3
15	Near Infrared Photoimmunotherapy of Cancer. , 2021, , .		0
16	Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. Scientific Reports, 2021, 11, 1693.	3.3	48
17	Fluorescence Imaging of Tumor-Accumulating Antibody-IR700 Conjugates Prior to Near-Infrared Photoimmunotherapy (NIR-PIT) Using a Commercially Available Camera Designed for Indocyanine Green. Molecular Pharmaceutics, 2021, 18, 1238-1246.	4.6	15
18	Diagnostic imaging in nearâ€infrared photoimmunotherapy using a commercially available camera for indocyanine green. Cancer Science, 2021, 112, 1326-1330.	3.9	13

#	Article	IF	Citations
19	Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. Advanced Therapeutics, 2021, 4, 2000269.	3.2	27
20	Quantitative analysis of vascular changes during photoimmunotherapy using speckle variance optical coherence tomography (SV-OCT). Biomedical Optics Express, 2021, 12, 1804.	2.9	3
21	Norcyanine-Carbamates Are Versatile Near-Infrared Fluorogenic Probes. Journal of the American Chemical Society, 2021, 143, 5674-5679.	13.7	51
22	Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10, 3135-3151.	6.0	19
23	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. Cancers, 2021, 13, 2535.	3.7	47
24	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. EBioMedicine, 2021, 67, 103345.	6.1	21
25	Expanding the application of cancer near-infrared photoimmunotherapy. EBioMedicine, 2021, 68, 103416.	6.1	3
26	Endoscopic nearâ€infrared photoimmunotherapy in an orthotopic head and neck cancer model. Cancer Science, 2021, 112, 3041-3049.	3.9	15
27	Near infrared photoimmunotherapy for cancers: A translational perspective. EBioMedicine, 2021, 70, 103501.	6.1	30
28	Electron Donors Rather Than Reactive Oxygen Species Needed for Therapeutic Photochemical Reaction of Near-Infrared Photoimmunotherapy. ACS Pharmacology and Translational Science, 2021, 4, 1689-1701.	4.9	16
29	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Molecular Cancer Therapeutics, 2021, 20, 2262-2273.	4.1	20
30	Future applications of and prospects for near-IR photoimmunotherapy: benefits and differences compared with photodynamic and photothermal therapy. Immunotherapy, 2021, 13, 1305-1307.	2.0	2
31	Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNÎ³-Dependent Tumor Vessel Regression. Cancer Research, 2021, 81, 3092-3104.	0.9	20
32	Real-time IR700 Fluorescence Imaging During Near-infrared Photoimmunotherapy Using a Clinically-approved Camera for Indocyanine Green. Cancer Diagnosis & Prognosis, 2021, 1, 29-34.	0.7	11
33	Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT. Gastric Cancer, 2020, 23, 82-94.	5.3	24
34	Near-Infrared Photoimmunotherapy: Photoactivatable Antibodyâ€“Drug Conjugates (ADCs). Bioconjugate Chemistry, 2020, 31, 28-36.	3.6	45
35	Conjugation Ratio, Light Dose, and pH Affect the Stability of Panitumumabâ€“IR700 for Near-Infrared Photoimmunotherapy. ACS Medicinal Chemistry Letters, 2020, 11, 1598-1604.	2.8	12
36	A near-infrared light-mediated cleavable linker strategy using the heptamethine cyanine chromophore. Methods in Enzymology, 2020, 641, 245-275.	1.0	12

#	Article	IF	Citations
37	Real-Time Fluorescence Imaging Using Indocyanine Green to Assess Therapeutic Effects of Near-Infrared Photoimmunotherapy in Tumor Model Mice. Molecular Imaging, 2020, 19, 153601212093496.	1.4	4
38	Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models. Vaccines, 2020, 8, 528.	4.4	23
39	Multi-Wavelength Fluorescence in Image-Guided Surgery, Clinical Feasibility and Future Perspectives. Molecular Imaging, 2020, 19, 153601212096233.	1.4	32
40	Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. Cancers, 2020, 12, 3747.	3.7	23
41	Wound healing after excision of subcutaneous tumors treated with nearâ€infrared photoimmunotherapy. Cancer Medicine, 2020, 9, 5932-5939.	2.8	4
42	Effect of Short PEG on Near-Infrared BODIPY-Based Activatable Optical Probes. ACS Omega, 2020, 5, 15657-15665.	3.5	4
43	Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6086-6091.	7.1	13
44	Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models. Cancer Immunology Research, 2020, 8, 345-355.	3.4	48
45	Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin. Cells, 2020, 9, 1019.	4.1	41
46	Current and new fluorescent probes for fluorescence-guided surgery. , 2020, , 75-114.		2
47	Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors. Cancers, 2020, 12, 2575.	3.7	25
48	Design strategy for germanium-rhodamine based pH-activatable near-infrared fluorescence probes suitable for biological applications. Communications Chemistry, 2019, 2, .	4.5	29
49	Near-Infrared Photoimmunotherapy of Cancer. Accounts of Chemical Research, 2019, 52, 2332-2339.	15.6	286
50	Photoimmunotherapy targeting biliaryâ€pancreatic cancer with humanized antiâ€TROP2 antibody. Cancer Medicine, 2019, 8, 7781-7792.	2.8	33
51	Nearâ€infrared photoimmunotherapy through bone. Cancer Science, 2019, 110, 3689-3694.	3.9	12
52	Enhanced nanodrug delivery in tumors after near-infrared photoimmunotherapy. Nanophotonics, 2019, 8, 1673-1688.	6.0	17
53	The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. Bioconjugate Chemistry, 2019, 30, 2624-2633.	3.6	35
54	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Cancer Immunology Research, 2019, 7, 401-413.	3.4	99

#	Article	IF	Citations
55	Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2019, 20, 1234-1248.	3.4	48
56	Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Scientific Reports, 2019, 9, 2084.	3.3	57
57	Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination. Gastric Cancer, 2019, 22, 463-472.	5.3	25
58	Activatable Near-Infrared Fluorescence Imaging Using PEGylated Bacteriochlorin-Based Chlorin and BODIPY-Dyads as Probes for Detecting Cancer. Bioconjugate Chemistry, 2019, 30, 169-183.	3.6	29
59	Near Infrared Photoimmunotherapy for Cancer. , 2019, , .		2
60	3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo. Journal of Controlled Release, 2018, 279, 171-180.	9.9	20
61	Near Infrared Photoimmunotherapy with Combined Exposure of External and Interstitial Light Sources. Molecular Pharmaceutics, 2018, 15, 3634-3641.	4.6	40
62	Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycinâ€“Antibody Conjugate. Molecular Cancer Therapeutics, 2018, 17, 661-670.	4.1	24
63	Activatable fluorescent probes in fluorescence-guided surgery: Practical considerations. Bioorganic and Medicinal Chemistry, 2018, 26, 925-930.	3.0	46
64	Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Central Science, 2018, 4, 1559-1569.	11.3	171
65	Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Science, 2018, 109, 1902-1908.	3.9	37
66	Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers. Oncotarget, 2018, 9, 11159-11169.	1.8	40
67	Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget, 2018, 9, 19026-19038.	1.8	30
68	Implantable wireless powered light emitting diode (LED) for near-infrared photoimmunotherapy: device development and experimental assessmentin vitroandin vivo. Oncotarget, 2018, 9, 20048-20057.	1.8	21
69	Pitfalls on sample preparation for ex vivo imaging of resected cancer tissue using enzyme-activatable fluorescent probes. Oncotarget, 2018, 9, 36039-36047.	1.8	2
70	In Vivo Activation of Duocarmycinâ€“Antibody Conjugates by Near-Infrared Light. ACS Central Science, 2017, 3, 329-337.	11.3	125
71	A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. ACS Chemical Biology, 2017, 12, 1121-1132.	3.4	54
72	Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibodyâ€“Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. Bioconjugate Chemistry, 2017, 28, 1458-1469.	3.6	30

#	Article	IF	Citations
73	Cerenkov Radiationâ€“Induced Photoimmunotherapy with ¹⁸F-FDG. Journal of Nuclear Medicine, 2017, 58, 1395-1400.	5.0	21
74	Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Molecular Cancer Therapeutics, 2017, 16, 2201-2214.	4.1	59
75	Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Molecular Cancer Research, 2017, 15, 1153-1162.	3.4	69
76	Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo. Journal of Controlled Release, 2017, 260, 154-163.	9.9	21
77	Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 408-414.	4.1	25
78	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Antiâ€“CD44-Based NIR-PIT. Molecular Cancer Research, 2017, 15, 1667-1677.	3.4	64
79	Evaluation of Early Therapeutic Effects after Near-Infrared Photoimmunotherapy (NIR-PIT) Using Luciferaseâ€“Luciferin Photon-Counting and Fluorescence Imaging. Molecular Pharmaceutics, 2017, 14, 4628-4635.	4.6	26
80	Fluorescence-Guided Surgery. Frontiers in Oncology, 2017, 7, 314.	2.8	249
81	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget, 2017, 8, 8807-8817.	1.8	68
82	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget, 2017, 8, 10425-10436.	1.8	179
83	Near-infrared photoimmunotherapy: a comparison of light dosing schedules. Oncotarget, 2017, 8, 35069-35075.	1.8	32
84	A topically-sprayable, activatable fluorescent and retaining probe, SPiDER-Î²Gal for detecting cancer: Advantages of anchoring to cellular proteins after activation. Oncotarget, 2017, 8, 39512-39521.	1.8	20
85	Characteristics of ovarian cancer detection by a near-infrared fluorescent probe activated by human NAD(P)H: quinone oxidoreductase isozyme 1 (hNQO1). Oncotarget, 2017, 8, 61181-61192.	1.8	10
86	Avoiding thermal injury during near-infrared photoimmunotherapy (NIR-PIT): the importance of NIR light power density. Oncotarget, 2017, 8, 113194-113201.	1.8	32
87	Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy. Oncotarget, 2017, 8, 104295-104302.	1.8	24
88	Concepts in Diagnostic Probe Design. , 2017, , 177-200.		0
89	Eliciting Host Immunity Selectively against Cancer Cells Treated with Silica-Phthalocyanine-Based Near Infrared Photoimmunotherapy. , 2017, , .		0
90	Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging. Oncotarget, 2016, 7, 14143-14152.	1.8	32

#	Article	IF	Citations
91	Near infrared photoimmunotherapy with an anti-mesothelin antibody. Oncotarget, 2016, 7, 23361-23369.	1.8	44
92	Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget, 2016, 7, 14324-14335.	1.8	42
93	Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics, 2016, 6, 862-874.	10.0	71
94	Alterations of filopodia by near infrared photoimmunotherapy: evaluation with 3D low-coherent quantitative phase microscopy. Biomedical Optics Express, 2016, 7, 2738.	2.9	11
95	Rapid diagnosis of lymph node metastasis in breast cancer using a new fluorescent method with Î³-glutamyl hydroxymethyl rhodamine green. Scientific Reports, 2016, 6, 27525.	3.3	22
96	Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT). Journal of Controlled Release, 2016, 232, 1-8.	9.9	26
97	Effect of charge localization on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates. Molecular BioSystems, 2016, 12, 3046-3056.	2.9	35
98	Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?. Bioconjugate Chemistry, 2016, 27, 2225-2238.	3.6	726
99	Surgical tissue handling methods to optimize ex vivo fluorescence with the activatable optical probe Î³â€glutamyl hydroxymethyl rhodamine green. Contrast Media and Molecular Imaging, 2016, 11, 572-578.	0.8	9
100	Near infrared photoimmunotherapy of Bâ€cell lymphoma. Molecular Oncology, 2016, 10, 1404-1414.	4.6	46
101	Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Science Translational Medicine, 2016, 8, 352ra110.	12.4	163
102	Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Scientific Reports, 2016, 6, 27871.	3.3	64
103	Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer, 2016, 16, 37.	2.6	34
104	Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology. Current Opinion in Chemical Biology, 2016, 33, 32-38.	6.1	39
105	Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer. Molecular Cancer Therapeutics, 2016, 15, 402-411.	4.1	23
106	Role of Fluorophore Charge on the In Vivo Optical Imaging Properties of Near-Infrared Cyanine Dye/Monoclonal Antibody Conjugates. Bioconjugate Chemistry, 2016, 27, 404-413.	3.6	57
107	Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy. Nanoscale, 2016, 8, 12504-12509.	5.6	86
108	Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer. Oncotarget, 2016, 7, 79408-79416.	1.8	17

#	Article	IF	Citations
109	MR imaging biomarkers for evaluating therapeutic effects shortly after near infrared photoimmunotherapy. Oncotarget, 2016, 7, 17254-17264.	1.8	19
110	Dynamic fluorescent imaging with the activatable probe, Î³-glutamyl hydroxymethyl rhodamine green in the detection of peritoneal cancer metastases: Overcoming the problem of dilution when using a sprayable optical probe. Oncotarget, 2016, 7, 51124-51137.	1.8	15
111	Rapid intraoperative visualization of breast lesions with Î³-glutamyl hydroxymethyl rhodamine green. Scientific Reports, 2015, 5, 12080.	3.3	89
112	Nearâ€IR Lightâ€Mediated Cleavage of Antibodyâ€“Drug Conjugates Using Cyanine Photocages. Angewandte Chemie - International Edition, 2015, 54, 13635-13638.	13.8	140
113	Near Infrared Photoimmunotherapy in the Treatment of Pleural Disseminated NSCLC: Preclinical Experience. Theranostics, 2015, 5, 698-709.	10.0	81
114	Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS ONE, 2015, 10, e0136829.	2.5	69
115	Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Advances, 2015, 5, 25105-25114.	3.6	34
116	Sensitive Î²-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo. Nature Communications, 2015, 6, 6463.	12.8	334
117	Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells. Breast Cancer Research and Treatment, 2015, 149, 597-605.	2.5	24
118	Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies?. Journal of Nuclear Medicine, 2015, 56, 140-144.	5.0	66
119	Near infrared photoimmunotherapy for lung metastases. Cancer Letters, 2015, 365, 112-121.	7.2	62
120	Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. Journal of Surgical Research, 2015, 197, 5-11.	1.6	27
121	Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics, 2015, 12, 2151-2157.	4.6	59
122	Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Annals of Surgical Oncology, 2015, 22, 1469-1474.	1.5	22
123	Magnetic Resonance Sentinel Lymph Node Imaging of the Prostate with Gadofosveset Trisodiumâ€“Albumin. Academic Radiology, 2015, 22, 646-652.	2.5	17
124	Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 141-150.	4.1	81
125	Preparation and long-term biodistribution studies of a PAMAM dendrimer G5â€“Gd-BnDOTA conjugate for lymphatic imaging. Nanomedicine, 2015, 10, 1423-1437.	3.3	31
126	Impact of C4â€²-O-Alkyl Linker on in Vivo Pharmacokinetics of Near-Infrared Cyanine/Monoclonal Antibody Conjugates. Molecular Pharmaceutics, 2015, 12, 3303-3311.	4.6	41

#	Article	IF	Citations
127	Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine, 2015, 10, 1139-1147.	3.3	53
128	Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer. PLoS ONE, 2015, 10, e0121989.	2.5	56
129	Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget, 2015, 6, 19747-19758.	1.8	41
130	Near infrared photo-immunotherapy: A newly developed, target cell-specific cancer theranostic technology. , 2015, , .		0
131	Photoimmunotherapy of Gastric Cancer Peritoneal Carcinomatosis in a Mouse Model. PLoS ONE, 2014, 9, e113276.	2.5	65
132	Real-time monitoring of hemodynamic changes in tumor vessels during photoimmunotherapy using optical coherence tomography. Journal of Biomedical Optics, 2014, 19, 098004.	2.6	18
133	Dynamic fluorescent imaging with indocyanine green for monitoring the therapeutic effects of photoimmunotherapy. Contrast Media and Molecular Imaging, 2014, 9, 276-282.	0.8	15
134	MR lymphangiography with intradermal gadofosveset and human serum albumin in mice and primates. Journal of Magnetic Resonance Imaging, 2014, 40, 691-697.	3.4	9
135	Fluorescenceâ€lifetime molecular imaging can detect invisible peritoneal ovarian tumors in bloody ascites. Cancer Science, 2014, 105, 308-314.	3.9	5
136	The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy. Molecular Cancer Therapeutics, 2014, 13, 426-432.	4.1	61
137	Magnetic Resonance Lymphography of the Thoracic Duct after Interstitial Injection of Gadofosveset Trisodium: A Pilot Dosing Study in a Porcine Model. Lymphatic Research and Biology, 2014, 12, 32-36.	1.1	13
138	Activatable Organic Near-Infrared Fluorescent Probes Based on a Bacteriochlorin Platform: Synthesis and Multicolor in Vivo Imaging with a Single Excitation. Bioconjugate Chemistry, 2014, 25, 362-369.	3.6	41
139	Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. Bioconjugate Chemistry, 2014, 25, 2093-2100.	3.6	68
140	The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer, 2014, 14, 389.	2.6	46
141	Dendrimers as high relaxivity <scp>MR</scp> contrast agents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2014, 6, 155-162.	6.1	39
142	Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Molecular Oncology, 2014, 8, 620-632.	4.6	95
143	Minibody-Indocyanine Green Based Activatable Optical Imaging Probes: The Role of Short Polyethylene Glycol Linkers. ACS Medicinal Chemistry Letters, 2014, 5, 411-415.	2.8	35
144	Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?. Theranostics, 2014, 4, 81-89.	10.0	792

#	Article	IF	Citations
145	New technologies of cancer cell-specific molecular imaging and near infrared photoimmunotherapy. Drug Delivery System, 2014, 29, 274-284.	0.0	0
146	Polychromatic in vivo imaging of multiple targets using visible and near infrared light. Advanced Drug Delivery Reviews, 2013, 65, 1112-1119.	13.7	12
147	Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors. ACS Nano, 2013, 7, 717-724.	14.6	237
148	In vivo realâ€time lymphatic draining using quantumâ€dot optical imaging in mice. Contrast Media and Molecular Imaging, 2013, 8, 96-100.	0.8	17
149	Short PEG-Linkers Improve the Performance of Targeted, Activatable Monoclonal Antibody-Indocyanine Green Optical Imaging Probes. Bioconjugate Chemistry, 2013, 24, 811-816.	3.6	53
150	Monoclonal antibodyâ€“fluorescent probe conjugates for in vivo target-specific cancer imaging: toward clinical translation. Therapeutic Delivery, 2013, 4, 523-525.	2.2	4
151	Acute Cytotoxic Effects of Photoimmunotherapy Assessed by ¹⁸F-FDG PET. Journal of Nuclear Medicine, 2013, 54, 770-775.	5.0	30
152	Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. Journal of Biomedical Optics, 2013, 18, 101304.	2.6	18
153	Endoscopic molecular imaging of cancer. Future Oncology, 2013, 9, 1501-1513.	2.4	3
154	Improving the Efficacy of Photoimmunotherapy (PIT) using a Cocktail of Antibody Conjugates in a Multiple Antigen Tumor Model. Theranostics, 2013, 3, 357-365.	10.0	74
155	Recipe for a new imaging biomarker: carefully combine target, reagent, and technology. Kidney International, 2012, 81, 129-131.	5.2	1
156	The Use of Fluorescent Proteins for Developing Cancer-Specific Target Imaging Probes. Methods in Molecular Biology, 2012, 872, 191-204.	0.9	10
157	Real-time Monitoring of In Vivo Acute Necrotic Cancer Cell Death Induced by Near Infrared Photoimmunotherapy Using Fluorescence Lifetime Imaging. Cancer Research, 2012, 72, 4622-4628.	0.9	77
158	Response to Comment on â€œRapid Cancer Detection by Topically Spraying a Î³-Glutamyltranspeptidaseâ€“Activated Fluorescent Probeâ€. Science Translational Medicine, 2012, 4, .	12.4	1
159	Medical Uses of Fluorescence Imaging: Bringing Disease to Light. IEEE Journal of Selected Topics in Quantum Electronics, 2012, 18, 1140-1146.	2.9	18
160	In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Research, 2012, 14, R61.	5.0	60
161	Gadolinium MRI Contrast Agents Based on Triazine Dendrimers: Relaxivity and In Vivo Pharmacokinetics. Bioconjugate Chemistry, 2012, 23, 2291-2299.	3.6	49
162	Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconjugate Chemistry, 2012, 23, 604-609.	3.6	136

#	Article	IF	Citations
163	Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer, 2012, 12, 345.	2.6	86
164	Galactosyl Human Serum Albumin-NMP1 Conjugate: A Near Infrared (NIR)-Activatable Fluorescence Imaging Agent to Detect Peritoneal Ovarian Cancer Metastases. Bioconjugate Chemistry, 2012, 23, 1671-1679.	3.6	60
165	MR and optical imaging of early micrometastases in lymph nodes: triple labeling with nanoâ€sized agents yielding distinct signals. Contrast Media and Molecular Imaging, 2012, 7, 247-253.	0.8	19
166	Molecular imaging of tumor invasion and metastases: the role of MRI. NMR in Biomedicine, 2011, 24, 561-568.	2.8	23
167	Target-Cancer-Cell-Specific Activatable Fluorescence Imaging Probes: Rational Design and in Vivo Applications. Accounts of Chemical Research, 2011, 44, 83-90.	15.6	353
168	Activatable Optical Imaging with a Silica-Rhodamine Based Near Infrared (SiR700) Fluorophore: A comparison with cyanine based dyes. Bioconjugate Chemistry, 2011, 22, 2531-2538.	3.6	53
169	Biologically Optimized Nanosized Molecules and Particles: More than Just Size. Bioconjugate Chemistry, 2011, 22, 993-1000.	3.6	149
170	Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibodyâ€“Indocyanine Green (ICG) Conjugate. Bioconjugate Chemistry, 2011, 22, 1700-1705.	3.6	128
171	Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chemical Society Reviews, 2011, 40, 4626.	38.1	198
172	Rapid Cancer Detection by Topically Spraying a Î³-Glutamyltranspeptidaseâ€“Activated Fluorescent Probe. Science Translational Medicine, 2011, 3, 110ra119.	12.4	404
173	Cancer cellâ€“selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature Medicine, 2011, 17, 1685-1691.	30.7	851
174	Quantitative and specific molecular imaging of cancer with labeled engineered monoclonal antibody fragments. Therapeutic Delivery, 2011, 2, 345-358.	2.2	4
175	Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 1001-1008.	3.3	116
176	A Portable Fluorescence Camera for Testing Surgical Specimens in the Operating Room: Description and Early Evaluation. Molecular Imaging and Biology, 2011, 13, 862-867.	2.6	17
177	Selfâ€illuminating in vivo lymphatic imaging using a bioluminescence resonance energy transfer quantum dot nanoâ€particle. Contrast Media and Molecular Imaging, 2011, 6, 55-59.	0.8	32
178	Optimizing quantitative in vivo fluorescence imaging with nearâ€infrared quantum dots. Contrast Media and Molecular Imaging, 2011, 6, 148-152.	0.8	11
179	Near infrared fluorescenceâ€guided realâ€time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. International Journal of Cancer, 2011, 129, 1671-1677.	5.1	102
180	In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System. Cancer Prevention Research, 2011, 4, 767-773.	1.5	15

#	Article	IF	Citations
181	New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging. Chemical Reviews, 2010, 110, 2620-2640.	47.7	1,927
182	Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast Media and Molecular Imaging, 2010, 5, 1-8.	0.8	29
183	Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. International Journal of Pharmaceutics, 2010, 383, 293-296.	5.2	99
184	Semiquantitative assessment of the microdistribution of fluorescenceâ€labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Science, 2010, 101, 820-825.	3.9	18
185	Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine, 2010, 5, 765-776.	3.3	42
186	New Nanosized Biocompatible MR Contrast Agents Based on Lysine-Dendri-Graft Macromolecules. Bioconjugate Chemistry, 2010, 21, 955-960.	3.6	41
187	Biodistribution and Excretion of Monosaccharideâ"Albumin Conjugates Measured with in Vivo Near-Infrared Fluorescence Imaging. Bioconjugate Chemistry, 2010, 21, 1925-1932.	3.6	21
188	Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncology, The, 2010, 11, 589-595.	10.7	72
189	Magnetic resonance lymphangiography with a nano-sized gadolinium-labeled dendrimer in small and large animal models. Nanomedicine, 2010, 5, 1183-1191.	3.3	39
190	Two-Step Synthesis of Galactosylated Human Serum Albumin as a Targeted Optical Imaging Agent for Peritoneal Carcinomatosis. Journal of Medicinal Chemistry, 2010, 53, 1579-1586.	6.4	23
191	In vivomolecular imaging using nanomaterials: Generalin vivocharacteristics of nano-sized reagents and applications for cancer diagnosis (Review). Molecular Membrane Biology, 2010, 27, 274-285.	2.0	65
192	High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation. Molecular BioSystems, 2010, 6, 888.	2.9	61
193	In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Molecular Cancer Therapeutics, 2009, 8, 232-239.	4.1	95
194	Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine, 2009, 4, 411-419.	3.3	57
195	Toxicity of Organic Fluorophores Used in Molecular Imaging: Literature Review. Molecular Imaging, 2009, 8, 7290.2009.00031.	1.4	358
196	New Approaches to Lymphatic Imaging. Lymphatic Research and Biology, 2009, 7, 205-214.	1.1	41
197	Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. Journal of Biomedical Optics, 2009, 14, 014023.	2.6	25
198	Dendrimers in medical nanotechnology. IEEE Engineering in Medicine and Biology Magazine, 2009, 28, 12-22.	0.8	78

#	Article	IF	Citations
199	Nanoparticles in sentinel lymph node mapping. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 610-623.	6.1	51
200	Multicolor inÂvivo targeted imaging to guide realâ€time surgery of HER2â€positive micrometastases in a twoâ€tumor coincident model of ovarian cancer. Cancer Science, 2009, 100, 1099-1104.	3.9	56
201	In Vivo Real-Time, Multicolor, Quantum Dot Lymphatic Imaging. Journal of Investigative Dermatology, 2009, 129, 2818-2822.	0.7	76
202	Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nature Medicine, 2009, 15, 104-109.	30.7	742
203	Tumor-Specific Detection of an Optically Targeted Antibody Combined with a Quencher-Conjugated Neutravidin â€œQuencher-Chaserâ€: A Dual â€œQuench and Chaseâ€•Strategy to Improve Target to Nontarget Ratios for Molecular Imaging of Cancer. Bioconjugate Chemistry, 2009, 20, 147-154.	3.6	30
204	In Vivo Stable Tumor-Specific Painting in Various Colors Using Dehalogenase-Based Protein-Tag Fluorescent Ligands. Bioconjugate Chemistry, 2009, 20, 1367-1374.	3.6	40
205	Dual-Modality Molecular Imaging Using Antibodies Labeled with Activatable Fluorescence and a Radionuclide for Specific and Quantitative Targeted Cancer Detection. Bioconjugate Chemistry, 2009, 20, 2177-2184.	3.6	92
206	In vivo multiple color lymphatic imaging using upconverting nanocrystals. Journal of Materials Chemistry, 2009, 19, 6481.	6.7	112
207	Activatable optical imaging probes with various fluorophore-quencher combinations. Proceedings of SPIE, 2009, , .	0.8	2
208	Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncology, 2009, 5, 1501-1511.	2.4	148
209	Fluorescence in vivo imaging of live tumor cells with pH-activatable targeted probes via receptor-mediated endocytosis. , 2009, , .		0
210	Fluorophoreâ"Quencher Based Activatable Targeted Optical Probes for Detecting in Vivo Cancer Metastases. Molecular Pharmaceutics, 2009, 6, 386-395.	4.6	98
211	Molecular probes for the in vivo imaging of cancer. Molecular BioSystems, 2009, 5, 1279.	2.9	65
212	In vivo Molecular Imaging of Cancer with a Quenching Near-Infrared Fluorescent Probe Using Conjugates of Monoclonal Antibodies and Indocyanine Green. Cancer Research, 2009, 69, 1268-1272.	0.9	306
213	H-Type Dimer Formation of Fluorophores: A Mechanism for Activatable, in Vivo Optical Molecular Imaging. ACS Chemical Biology, 2009, 4, 535-546.	3.4	167
214	Fluorescence Imaging of Tumors with â€œSmartâ€•pH-Activatable Targeted Probes. Methods in Molecular Biology, 2009, 574, 47-62.	0.9	14
215	Lymphangiogenesis and Imaging of the Lymphatics in Cancer. Cancer Metastasis - Biology and Treatment, 2009, , 159-184.	0.1	1
216	Toxicity of organic fluorophores used in molecular imaging: literature review. Molecular Imaging, 2009, 8, 341-54.	1.4	148

#	Article	IF	Citations
217	Determination of Optimal Rhodamine Fluorophore for in Vivo Optical Imaging. Bioconjugate Chemistry, 2008, 19, 1735-1742.	3.6	72
218	Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine, 2008, 3, 703-717.	3.3	1,691
219	Multiplexing with Multispectral Imaging: From Mice to Microscopy. ILAR Journal, 2008, 49, 78-88.	1.8	65
220	Multi-excitation near infrared (NIR) spectral fluorescence imaging using organic fluorophores. Proceedings of SPIE, 2008, , .	0.8	1
221	Dendrimer-Based Contrast Agents for Molecular Imaging. Current Topics in Medicinal Chemistry, 2008, 8, 1180-1186.	2.1	128
222	Activatable Fluorescence Probes for Targeted Molecular Imaging of Cancer. , 2008, , .		0
223	MR Lymphangiography Using Nano-Sized Paramagnetic Contrast Agents with Dendrimer Cores. , 2008, , 9-23.		0
224	Spectral Fluorescence Molecular Imaging of Lung Metastases Targeting HER2/neu. Clinical Cancer Research, 2007, 13, 2936-2945.	7.0	74
225	Activatable Fluorescent Molecular Imaging of Peritoneal Metastases following Pretargeting with a Biotinylated Monoclonal Antibody. Cancer Research, 2007, 67, 3809-3817.	0.9	54
226	Two-color in vivo dynamic contrast-enhanced pharmacokinetic imaging. Journal of Biomedical Optics, 2007, 12, 034016.	2.6	12
227	A Target Cellâ€“Specific Activatable Fluorescence Probe for In vivo Molecular Imaging of Cancer Based on a Self-Quenched Avidin-Rhodamine Conjugate. Cancer Research, 2007, 67, 2791-2799.	0.9	105
228	D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green. Journal of Biomedical Optics, 2007, 12, 051501.	2.6	36
229	In vivoDiagnosis of Epidermal Growth Factor Receptor Expression using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies. Clinical Cancer Research, 2007, 13, 6639-6648.	7.0	110
230	In Vivo Molecular Imaging to Diagnose and Subtype Tumors through Receptor-Targeted Optically Labeled Monoclonal Antibodies. Neoplasia, 2007, 9, 1021-1029.	5.3	94
231	Preparation and Preliminary Evaluation of a Biotin-Targeted, Lectin-Targeted Dendrimer-Based Probe for Dual-Modality Magnetic Resonance and Fluorescence Imaging. Bioconjugate Chemistry, 2007, 18, 1474-1482.	3.6	119
232	An Enzymatically Activated Fluorescence Probe for Targeted Tumor Imaging. Journal of the American Chemical Society, 2007, 129, 3918-3929.	13.7	161
233	A Self-Quenched Galactosamine-Serum Albumin-RhodamineX Conjugate: A â€œSmartâ€•Fluorescent Molecular Imaging Probe Synthesized with Clinically Applicable Material for Detecting Peritoneal Ovarian Cancer Metastases. Clinical Cancer Research, 2007, 13, 6335-6343.	7.0	37
234	Toward Improved Syntheses of Dendrimer-Based Magnetic Resonance Imaging Contrast Agents:â€‰ New Bifunctional Diethylenetriaminepentaacetic Acid Ligands and Nonaqueous Conjugation Chemistry. Journal of Medicinal Chemistry, 2007, 50, 3185-3193.	6.4	59

#	Article	IF	Citations
235	Multimodal Nanoprobes for Radionuclide and Five-Color Near-Infrared Optical Lymphatic Imaging. ACS Nano, 2007, 1, 258-264.	14.6	183
236	Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms. Contrast Media and Molecular Imaging, 2007, 2, 82-87.	0.8	6
237	MR lymphangiography using dendrimer-based contrast agents: A comparison at 1.5T and 3.0T. Magnetic Resonance in Medicine, 2007, 57, 431-436.	3.0	13
238	A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. Journal of Magnetic Resonance Imaging, 2007, 25, 866-871.	3.4	136
239	Two-Color Lymphatic Mapping Using Ig-Conjugated Near Infrared Optical Probes. Journal of Investigative Dermatology, 2007, 127, 2351-2356.	0.7	48
240	Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Science, 2007, 98, 1727-1733.	3.9	39
241	Real-Time Fluorescence-Enhanced Imaging as an Aid to Surgery in Ovarian Cancer. IEEE Journal of Selected Topics in Quantum Electronics, 2007, 13, 1602-1609.	2.9	6
242	Simultaneous Multicolor Imaging of Five Different Lymphatic Basins Using Quantum Dots. Nano Letters, 2007, 7, 1711-1716.	9.1	320
243	Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location. Cancer Immunology, Immunotherapy, 2007, 56, 1119-1131.	4.2	16
244	Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Research and Treatment, 2007, 103, 23-28.	2.5	118
245	Dendrimer-Based Nanoprobe for Dual Modality Magnetic Resonance and Fluorescence Imaging. Nano Letters, 2006, 6, 1459-1463.	9.1	259
246	In Vivo Spectral Fluorescence Imaging of Submillimeter Peritoneal Cancer Implants Using a Lectin-Targeted Optical Agent. Neoplasia, 2006, 8, 607-IN2.	5.3	59
247	A Comparison of the Emission Efficiency of Four Common Green Fluorescence Dyes after Internalization into Cancer Cells. Bioconjugate Chemistry, 2006, 17, 1426-1431.	3.6	51
248	Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin. Biochemical and Biophysical Research Communications, 2006, 348, 807-813.	2.1	49
249	Macromolecular MRI contrast agents for imaging tumor angiogenesis. European Journal of Radiology, 2006, 60, 353-366.	2.6	143
250	Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: Comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. Journal of Controlled Release, 2006, 111, 343-351.	9.9	142
251	Imaging of the lymphatic system: new horizons. Contrast Media and Molecular Imaging, 2006, 1, 230-245.	0.8	128
252	Imaging Acute Renal Failure with Polyamine Dendrimer-Based MRI Contrast Agents. Nephron Clinical Practice, 2006, 103, c45-c49.	2.3	29

#	Article	IF	Citations
253	Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. Blood, 2005, 105, 2356-2363.	1.4	35
254	Nano-sized MRI contrast agents with dendrimer cores. Advanced Drug Delivery Reviews, 2005, 57, 2271-2286.	13.7	420
255	Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice. Kidney International, 2005, 67, 2159-2167.	5.2	55
256	Detection of Lymph Node Involvement in Hematologic Malignancies Using Micromagnetic Resonance Lymphangiography with a Gadolinum-Labeled Dendrimer Nanoparticle. Neoplasia, 2005, 7, 984-991.	5.3	52
257	Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation. Clinical Cancer Research, 2004, 10, 7712-7720.	7.0	80
258	Micro-MRI methods to detect renal cysts in mice. Kidney International, 2004, 65, 1511-1516.	5.2	27
259	Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidinâ€“dendrimer complex. Journal of Controlled Release, 2004, 95, 133-141.	9.9	39
260	Polyamine dendrimerâ€based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. Journal of Magnetic Resonance Imaging, 2004, 20, 512-518.	3.4	72
261	Lymphatic Drainage Imaging of Breast Cancer in Mice by Micro-Magnetic Resonance Lymphangiography Using a Nano-Size Paramagnetic Contrast Agent. Journal of the National Cancer Institute, 2004, 96, 703-708.	6.3	149
262	Dendrimer-Based Nanosized MRI Contrast Agents. Current Pharmaceutical Biotechnology, 2004, 5, 539-549.	1.6	143
263	Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magnetic Resonance in Medicine, 2003, 50, 758-766.	3.0	109
264	Activated Clearance of a Biotinylated Macromolecular MRI Contrast Agent from the Blood Pool Using an Avidin Chase. Bioconjugate Chemistry, 2003, 14, 1044-1047.	3.6	31
265	Macromolecular MRI Contrast Agents with Small Dendrimers:â€‰ Pharmacokinetic Differences between Sizes and Cores. Bioconjugate Chemistry, 2003, 14, 388-394.	3.6	254
266	Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. Journal of Materials Chemistry, 2003, 13, 1523.	6.7	44
267	Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application. Molecular Imaging, 2003, 2, 153535002003031.	1.4	34
268	Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application. Molecular Imaging, 2003, 2, 1-10.	1.4	160
269	Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Research, 2003, 63, 271-6.	0.9	93
270	Dynamic Micro-MRI of Liver Micrometastasis with a Novel Liver Macromolecular MR Contrast Agent DAB-Am64-(1B4M-Gd)64. Academic Radiology, 2002, 9, S452-S454.	2.5	6

#	Article	IF	Citations
271	Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. Kidney International, 2002, 61, 1980-1985.	5.2	87
272	Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. Journal of Nuclear Medicine, 2002, 43, 658-63.	5.0	109
273	Avidin-dendrimer-(1B4M-Gd)₂₅₄:â€‰ A Tumor-Targeting Therapeutic Agent for Gadolinium Neutron Capture Therapy of Intraperitoneal Disseminated Tumor Which Can Be Monitored by MRI. Bioconjugate Chemistry, 2001, 12, 587-593.	3.6	106
274	Comparison of the Macromolecular MR Contrast Agents with Ethylenediamine-Core versus Ammonia-Core Generation-6 Polyamidoamine Dendrimer. Bioconjugate Chemistry, 2001, 12, 100-107.	3.6	77
275	Microâ€MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimerâ€based MR contrast agents. Journal of Magnetic Resonance Imaging, 2001, 14, 705-713.	3.4	86
276	Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine. Magnetic Resonance in Medicine, 2001, 46, 457-464.	3.0	41
277	3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magnetic Resonance in Medicine, 2001, 46, 579-585.	3.0	45
278	Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magnetic Resonance in Medicine, 2001, 46, 781-788.	3.0	116
279	Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core. Magnetic Resonance in Medicine, 2001, 46, 795-802.	3.0	79
280	Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magnetic Resonance in Medicine, 2001, 46, 1169-1173.	3.0	127
281	3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magnetic Resonance in Medicine, 2001, 45, 454-460.	3.0	143
282	Polysplenia associated with semiannular pancreas. European Radiology, 2001, 11, 1639-1641.	4.5	15
283	Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1334-1339.	2.1	97
284	Paraneoplastic syndromes associated with ovarian neoplasms. International Journal of Clinical Oncology, 2000, 5, 79-84.	2.2	3
285	Evaluation of the in Vivo Biodistribution of Indium-111 and Yttrium-88 Labeled Dendrimer-1B4M-DTPA and Its Conjugation with Anti-Tac Monoclonal Antibody. Bioconjugate Chemistry, 1999, 10, 103-111.	3.6	109
286	Inflammation-seeking scintigraphy with radiolabeled biotinylated polyclonal IgG followed by the injection of avidin chase. Nuclear Medicine and Biology, 1996, 23, 29-32.	0.6	5
287	Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA125 Monoclonal Antibody. Japanese Journal of Cancer Research, 1996, 87, 655-661.	1.7	5
288	Comparison of the Chase Effects of Avidin, Streptavidin, Neutravidin, and Avidin-Ferritin on a Radiolabeled Biotinylated Anti-tumor Monoclonal Antibody. Japanese Journal of Cancer Research, 1995, 86, 310-314.	1.7	23

#	Article	IF	Citations
289	Uptake of pentavalent technetium-99m dimercaptosuccinic acid in idiopathic synovial chondromatosis. Annals of Nuclear Medicine, 1995, 9, 153-155.	2.2	5
290	Scintigraphic detection of neural-cell-derived small-cell lung cancer using glioma-specific antibody. Journal of Cancer Research and Clinical Oncology, 1994, 120, 259-262.	2.5	14
291	Production of Multiple Growth Factors by a Newly Established Human Thyroid Carcinoma Cell Line. Japanese Journal of Cancer Research, 1992, 83, 153-158.	1.7	33